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CXCR4 is a chemokine receptor frequently overexpressed on primary tumor cells. Organs to which these cancers metastasize
secrete CXCL12, the unique ligand for CXCR4, which stimulates invasion and metastasis to these sites. Similar to our previous
work with the chemoprotective phytochemical, 3,3 -diindolylmethane (DIM), we show here that genistein also downregulates
CXCR4 and CXCL12 and subsequently lowers the migratory and invasive potentials of breast and ovarian cancer cells. Moreover,
genistein and DIM elicit a signiﬁcantly greater cumulative eﬀect in lowering CXCR4 and CXCL12 levels than either compound
alone. Our data suggest a novel mechanism for the protective eﬀects of phytochemicals against cancer progression and indicate
that in combination, these compounds may prove even more eﬃcacious.
Copyright © 2009 Erin L. Hsu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Phytochemicals have long been implicated in a protec-
tive eﬀect for cancer. Soybean- and cruciferous vegetable-
enriched diets seem to be particularly protective, but
the mechanisms for this anticarcinogenicity are not fully
understood. Genistein, a dietary phytoestrogen belonging to
the isoﬂavone class of ﬂavonoids, is thought to have anti-
carcinogenic activities, particularly for breast and prostate
cancer [1, 2]. Dietary soy has been shown in mice to
inhibit prostate tumor growth through inhibition of cell
proliferation, increased apoptosis, and reduced microvessel
density [3]. Epidemiology studies of Asian women indicate
that consumption of a traditional diet high in soy confers
signiﬁcant protection against breast cancer [4].
3,3 -diindolylmethane (DIM), a breakdown product of
glucobrassicins, which are found in cruciferous vegetables,
has been shown in vivo to have protective eﬀects for breast
cancer [5]. We have shown previously that DIM lowers
the levels of CXCR4 and CXCL12, a chemokine receptor
and its unique ligand required for the metastasis of breast
cancer [6, 7]. In addition to mediating the directional
homing of primary breast cancer cells to secondary organ
sites, CXCR4 and CXCL12 are important in other aspects
of cancer progression, such as adhesion, proliferation, and
angiogenesis. These eﬀects are not limited to breast can-
cer, as the interaction between CXCR4 and CXCL12 is
implicated in the progression of many diﬀerent types of
cancer.
The biological eﬀects of genistein are extensive and
include antioxidant activity, weak estrogenic/antiestrogenic
activity, upregulation of apoptosis, inhibition of angiog-
enesis,inhibitionofDNAtopoisomeraseII,andinhibitionof
protein tyrosine kinases (PTKs). Genistein has been shown
to regulate speciﬁc sex steroid receptors, inhibit NFkB,
downregulate TGF-β, and inhibit EFG-stimulated growth.
Furthermore, genistein inhibits 2,3,7,8-tetrachlorodibenzo-
p-dioxin (dioxin)-induced CYP1A1 activity, and isoﬂavo-
nes can prevent the CYP1A1-mediated binding of
benzo[a]pyrene (B[a]P) metabolites to DNA [8].2 Journal of Oncology
Our previous observations that DIM downregulates
CXCR4 and CXCL12 in breast and ovarian cancer cells
represent a novel mechanism for the chemoprotective eﬀects
of this phytochemical. Here, we demonstrate that these
eﬀects are not unique to DIM, but can also be seen with
genistein. Interestingly, we see that the combined eﬀect
of DIM and genistein elicits a greater downregulation of
CXCR4 and CXCL12 than either compound alone, indicat-
ing that the phytochemicals used in combination may be
even more potent in their chemoprotective properties. We
alsodemonstratethatlikeDIM,genisteinspeciﬁcallyinhibits
chemotaxis and chemoinvasion of breast and ovarian cancer
cells toward CXCL12 in vitro.
2.MaterialsandMethods
2.1. Chemical Reagents and Cell Culture. Genistein was
purchased from Sigma (St. Louis, Mo, USA), DIM was
purchased from LKT Laboratories (St. Paul, Minn, USA),
and the remaining phytochemicals were a kind gift from Dr.
David Heber (University of California, Los Angeles, Calif,
USA). BG-1 cells were generously provided by Dr. Kenneth
Korach (National Institute of Environmental Health Sci-
ences, NC, USA). MCF-7 and MDA-MB-231 cells were pur-
chased from the American Type Culture Collection (ATCC,
Manassas, Va, USA). MCF-7 and BG-1 cells were main-
tained in Minimal Essential Medium. MDA-MB-231 cells
were maintained in Dulbecco’s Modiﬁed Eagle’s Medium
containing 4mM L-glutamine. All media were purchased
from Invitrogen (Carlsbad, Calif, USA) and supplemented
with 10% fetal bovine serum (FBS; Omega, Tarzana, Calif,
USA),100U/mLpenicillin/100μg/mLstreptomycinsolution
(Gemini Bio-Products, West Sacramento, Calif, USA), and
0.25U/mL Amphotericin B (Omega). Cells were maintained
at 37
◦C under 5% CO2. For all experiments, chemicals were
dissolved in DMSO and administered to cells with a ﬁnal
concentration of DMSO at 0.1% in the medium.
2.2. RNA Extraction, cDNA Synthesis, and Real-Time PCR.
RNA isolation, cDNA synthesis, and taqman multiplex
real-time PCR were performed as previously described
[6]. CXCR4 and CXCL12 cDNAs were ampliﬁed using
Assays on Demand (Aﬃnity Bioreagents, Golden, Colo, USA;
product numbers Hs00607978 s1 and Hs00171022 m1,
resp.; sequences proprietary). Quantities were normalized
to those for the 36B4 ribosomal housekeeping gene. The
forward and reverse primers used for 36B4 quantiﬁcation
were 5 -CCACGGTGCTGAACATGCT-3  and 5 -TCGAA-
CACCTGCTGGATGAC-3 , respectively. The 36B4 probe
sequence was 5 -Texas Red-ACCATCTCCCCCTTCTCC-
TTTGGGCT-Iowa Black-3 . All primers and probes were
purchased from Integrated DNA Technologies (Coralville,
Iowa, USA). Real-time PCR was carried out using the
ICycler IQ (BioRad, Hercules, Calif, USA) or 7500 Fast
(AppliedBiosystems,FosterCity,Calif,USA)understandard
protocols. Data were analyzed using the ICycler or ABI
software and Microsoft Excel, and signiﬁcance was evaluated
using Student’s t-test.
2.3. Flow Cytometry. For surface staining of CXCR4 and
intracellular staining of CXCL12, cells were grown to
70% conﬂuence and treated with genistein for 24 or 48
hours. In the case of CXCL12 quantiﬁcation, the cells were
also cotreated with 1μg/mL Brefeldin A (GlogiPlug; BD
PharMingen, Franklin Lakes, NJ, USA) for the ﬁnal six
hours of incubation to inhibit protein secretion. Cells were
harvested and stained as previously described [6, 9]w i t h
either primary CXCL12 antibody (R&D Cat. no. MAB350;
Minneapolis, Minn, USA), primary CXCR4 antibody (Aﬃn-
ity Bioreagents Cat. no. OPA1-01101; Ill, USA) or the
appropriate primary IgG isotype control antibody, followed
by staining with either goat antimouse or antirabbit IgG-
FITC secondary antibodies (BD-PharMingen and Caltag,
Carlsbad, Calif, USA, resp.). Fluorescence was quantiﬁed
using a FACScan analytic ﬂow cytometer (Becton Dickinson,
UCLA Flow Cytometry Core Facility). Data were analyzed
using FCS Express3 Lite Software (DeNovo, Inc., Thornhill,
ON, Canada).
2.4. Chemotaxis and Chemoinvasion Assays. Cells were pre-
treated with genistein, DIM, or the combination, followed
by chemotaxis and invasion assays, performed as we have
described previously [6]. After migration/invasion, MTS
assays (Promega, Madison, Wis) were performed in each
individual transwell to control for small variations in cell
number. After detection of the formazan product at 490nm,
cells on the inserts were washed with PBS and those on the
upper layer were gently removed with a prewet Q-tip. Cells
on the lower layer were ﬁxed in 100% methanol and stained
with crystal violet. Membranes were manually excised from
the inserts, mounted on microscope slides, and divided into
8 equal sections. Cells in one random viewing ﬁeld from
each section were counted at 40x magniﬁcation, and the
average was calculated. Average counts from each insert were
normalized to the equivalent MTS values. Data are expressed
as chemotaxis or chemoinvasion indices, which were deﬁned
as the normalized number of cells in the experimental
group relative to the control group. Statistical analyses were
performed using a two-tailed Student’s t-test.
3. Results
3.1. Genistein Downregulates CXCR4 and CXCL12 in Breast
and Ovarian Cancer Cells. MCF-7 and MDA-MB-231 breast
cancer cells and BG-1 ovarian cancer cells were treated with
concentrations of genistein ranging from 1–100μM( a ta
constant ﬁnal DMSO concentration) for 24 hours, after
which time CXCR4 and CXCL12 mRNAs were quantiﬁed
by real-time PCR. CXCR4 mRNA levels were signiﬁcantly
decreased at 1μM genistein in all three cell lines (Figures
1(a)–1(c)). Maximal downregulation was seen at 100μM,
50μM, and 30μM genistein in each cell line, respectively.
Signiﬁcant downregulation of CXCL12 mRNA occurred at a
concentration of 50μM genistein in MCF-7 cells and 10μM
genistein in BG-1 cells (Figures 1(a)–1(c)). Interestingly, low
doses of genistein (1–10μM) signiﬁcantly increased CXCL12
mRNA levels in MCF-7 cells, but had the opposite eﬀect inJournal of Oncology 3
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Figure 1: Dose-response curves for CXCR4 and CXCL12 mRNAs after treatment of breast and ovarian cancer cells with 1–10μM genistein. (a)
CXCR4 and CXCL12 mRNA quantiﬁcation after treatment of MCF-7 cells with increasing concentrations of genistein for 24 hours. (b)
CXCR4 quantiﬁcation after treatment of MDA-MB-231 cells with genistein for 24 hours. MDA-MB-231 cells do not express CXCL12 as
determined by real-time PCR. (c) CXCR4 and CXCL12 quantiﬁcation after treatment of BG-1 cells with increasing doses of genistein for
24 hours. All data were normalized to corresponding mRNA quantities for the 36B4 housekeeping gene. ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001;
relative to 0 μM genistein control.4 Journal of Oncology
BG-1 cells at these doses. MDA-MB-231 cells do not express
detectable levels of CXCL12.
Flow cytometric analysis was used to quantify surface
CXCR4 and intracellular CXCL12 expression. Cells were
treated with 30, 70, or 100μM genistein for 24 hours,
harvested, stained, and analyzed for surface expression levels
of CXCR4. Relative to DMSO-treated controls, CXCR4 was
found to be downregulated by genistein in MCF-7, MDA-
MB-231, and BG-1 cells at all three doses (Figures 2(a)–
2(c)). Analysis of CXCL12 intracellular expression showed
that relative to DMSO-treated control cells, CXCL12 levels
were reduced by all three doses of genistein in both MCF-7
and BG-1 cells (Figures 2(a), 2(c)).
3.2. Downregulation of CXCR4 and CXCL12 Is Greater
after Treatment with Both Genistein and DIM than with
Either Compound Alone. We previously found that DIM
downregulates CXCR4 and CXCL12 mRNAs and proteins
in invasive breast and ovarian cancer cells [6]. We therefore
tested whether the downregulation elicited by cotreatment
with both DIM and genistein was additive or synergistic in
these cell lines. Using real-time PCR, we quantiﬁed gene
expression after treatment of MDA-MB-231 (CXCR4 only)
or BG-1 (both CXCR4 and CXCL12) with 20μMD I M ,
100μM genistein, or the combination. We found that in
both cell lines, the degree of downregulation of CXCR4
was greater after treatment with both phytochemicals in
combination (Figures 3(a)-3(b)). In MDA-MB-231 cells,
DIM reduced levels of CXCR4 by 57%, genistein by 51%,
and the combination by 85% (Figure 3(a)). In BG-1 cells,
DIM downregulated CXCR4 by 49%, genistein by 79%, and
DIM + genistein by 90%. Similarly, DIM lowered the levels
of CXCL12 by 50%, genistein lowered levels by 84%, and
genistein by 91% (Figure 3(b)). These eﬀects cannot be
attributed to cytotoxicity, since neither DIM, genistein, nor
the combination was cytotoxic at these doses for the 24 hour
time period (data not shown).
3.3. Genistein Speciﬁcally Inhibits Chemotaxis and Chemoin-
vasion of Breast and Ovarian Cancer Cells toward CXCL12.
Since CXCR4 and CXCL12 mediate directional migration,
and since we saw previously that DIM inhibited chemotaxis
and chemoinvasion of these cells, we performed assays
to determine whether genistein could inhibit migration
through ﬁbronectin and/or invasion through matrigel. We
found that pretreatment with genistein inhibited the direc-
tional migration of MCF-7 cells, with a resulting migration
rate similar to the background rate (DMSO-treated cells
exposed to no CXCL12 gradient, Figure 4(a)). However,
we did not see a further reduction in migration after
cotreatment with genistein and DIM, presumably because
both chemicals used independently at these doses fully
reducedmigrationtobackgroundlevels.Thisresultindicates
that the degree to which genistein and DIM downregulate
surface CXCR4 levels at these doses may be suﬃcient to
signiﬁcantlyimpactthehomingofbreastcancercellstoareas
of high CXCL12 expression. As we have seen previously with
DIM, the inhibition of chemotaxis by genistein speciﬁcally
aﬀects migration toward CXCL12, since an inhibition of
MCF-7 cell chemotaxis toward FBS was not observed.
MCF-7 cells do not invade through matrigel (a synthetic
extracellular matrix), and we were therefore unable to evalu-
ate invasive potential in these cells. However, MDA-MB-231
breast cancer cells are invasive and we were able to quantify
both chemotactic and chemoinvasive potential in this cell
line. We found that genistein, DIM, and the combination
signiﬁcantly inhibited chemotaxis and chemoinvasion of
these cells toward CXCL12, but not toward IL-6, a known
in vitro chemoattractant for MDA-MB-231 cells (Figures
4(b)-4(c)). This result indicates that the inhibitory eﬀects
of DIM and genistein are speciﬁc for CXCL12-induced
chemoattraction/chemoinvasion and is not merely a general
eﬀectonmigrationorinvasion.Asimilarresultwasseenwith
BG-1 ovarian cancer cells, which are also invasive in vitro
(Figure 4(d)). These cells do not migrate through matrigel
toward IL-6 (data not shown), but did exhibit moderate
chemoinvasion toward FBS.
4. Discussion
The antiestrogenic activity of genistein may mediate, in part,
the protective eﬀects of soy for breast and other cancers [10].
Although other nonestrogenic mechanisms of action such
as PTK and topoisomerase II inhibition likely play a role
in these protective eﬀects, we describe here an additional
novel mechanistic pathway in which genistein and possibly
other phytochemicals may be protective. We have found that
genistein downregulates CXCR4 in the ER-positive (ER+)
breast cancer cell line, MCF-7, the ER-negative (ER−)b r e a s t
cancer cell line, MDA-MB-231, and the ER+ ovarian cancer
cell line, BG-1. Furthermore, CXCL12, the unique ligand for
CXCR4, is downregulated by genistein in both MCF-7 and
BG-1 cells. We show that this downregulation results in a
subsequent inhibition of migration and invasion of these
cells toward CXCL12 in vitro.
We found previously that DIM downregulates CXCR4
and CXCL12 in MCF-7, MDA-MB-231, and BG-1 cells [6].
We show here that when used in combination, the eﬀects of
DIM and genistein on CXCR4 and CXCL12 mRNA levels
are greater than with either compound alone, suggesting
that phytochemicals used in combination may increase the
eﬃcacy of their protective eﬀects. At 20μMD I Ma n d7 0μM
genistein, we did not ﬁnd the combination to further inhibit
chemotaxis or chemoinvasion of breast or ovarian cancer
cells since these concentrations of the phytochemicals fully
inhibit these processes. However, at the slightly lower doses
of 10μMD I Ma n d5 0μM genistein, the combination does
appear to be more eﬀective at inhibiting chemotaxis of
MDA-MB-231 cells. At these latter doses, the individual
phytochemicals did not fully reduce chemotaxis of these
cells to background levels. These results therefore suggest
that lower doses of the phytochemicals used in combination
may be equally or more eﬀective in chemoprotection than a
higher dose of a single phytochemical.
The mechanisms of action of DIM and genistein in
the downregulation of CXCR4 and CXCL12 remain to beJournal of Oncology 5
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Figure 2: Genistein downregulates CXCR4 surface expression and intracellular CXCL12 expression. Downregulation of CXCR4 protein
expression in MCF-7, MDA-MB-231, and BG-1 cells at concentrations of genistein ranging from 0–100μM for a 24-hour period (a)–
(c). Downregulation of intracellular CXCL12 protein expression in (a) MCF-7 and (c) BG-1 cells at 30–100μM genistein. Fluorescence
distribution plots depict one representative experiment. Isotype controls are represented by ﬁlled histograms. Mean ﬂuorescence intensities
(MFI) and their corresponding standard deviations are derived from three independent experiments.6 Journal of Oncology
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Figure 3: In combination, genistein and DIM are more eﬃcacious in the downregulation of CXCR4 and CXCL12 mRNAs than either compound
alone. The eﬀect of downregulation of CXCR4 in (a) MDA-MB-231 and (b) BG-1 cells by 20μM DIM and 100μM genistein in combination
is greater than their individual eﬀects. The same is seen in (b) BG-1 cells after CXCL12 quantiﬁcation. Ctl = DMSO alone; ∗∗P<. 01,
∗∗∗P<. 001.
determined. DIM and genistein both act as weak ago-
nists/antagonists of the estrogen receptor, and it is therefore
possible that the compounds can act through the same
mechanism. Importantly however, we see downregulation
of CXCR4 and a subsequent inhibition of chemotaxis and
chemoinvasion in MDA-MB-231 cells, which do not express
the estrogen receptor. On the other hand, DIM is a ligand
for the AHR, whereas genistein has not been shown to bind
the AHR in the cell lines we used. Genistein is a speciﬁc
PTK inhibitor as well as an inhibitor of topoisomerase II,
and may modulate TGF-β signal transduction [11, 12].
Interestingly, both genistein and DIM are known to inhibit
NFkB in breast, prostate, and pancreatic cancer cells [13–
15]. Since CXCR4 is regulated at the transcriptional level
by NFkB, it is plausible that the mechanism of CXCR4
and/or CXCL12 downregulation by DIM and/or genistein
could be through NFkB inactivation or downregulation
[16, 17].
Condoning the general use of genistein as a supplement
is at this point controversial. Soy products are extensively
consumed in Asian populations without apparent adverse
eﬀects, but experimental data have led to concerns about
the safety of genistein and other constituents of soy.
Although it was well tolerated, high doses of genistein
in chronic studies caused an increase in the weights of
the kidney, spleen, adrenal, and testes in male rats and
an increase in liver, kidney, spleen, ovary, and uterus
weights in female rats [18]. In the same study, histological
changes were seen in the reproductive organs of both
male and female rats. These ﬁndings were attributed to
the estrogenic properties of genistein. Genistein can behave
as both an estrogen and an antiestrogen, and the net
estrogenic eﬀect of the chemical has proven diﬃcult to
quantify [11]. A chronic exposure study very recently
carried out by the National Toxicology Program showed
a signiﬁcant increase in the incidence of mammary gland
adenoma and adenocarcinoma (combined) [19]. Impor-
tantly, the time of administration appears to signiﬁcantly
impact whether genistein elicits a protective, adverse, or no
eﬀect [20]. For example, dimethylbenzanthracene (DMBA)-
induced mammary cancer was reduced after prepubertal and
combined prepubertal and adult administration of genis-
tein, but not after prenatal-only or adult-only treatments
[2].
Dose also plays a critical role in the biological eﬀects
of genistein; although doses greater than 10μMo v e ra nJournal of Oncology 7
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Figure 4: DIM speciﬁcally inhibits chemotaxis and chemoinvasion of breast and ovarian cancer cells toward CXCL12. (a) Quantiﬁcation of
chemotaxisofMCF-7cellstowardCXCL12orFBSaftertreatmentwithDMSOalone(Ctl),20μMDIM,70μMgenistein,orthecombination
ofDIM+genisteinfor24hours.(b)-(c)ChemotaxisandchemoinvasionofMDA-MB-231cellstowardCXCL12orIL-6werequantiﬁedafter
pretreatment with DIM and/or genistein as in (a). (d) Quantiﬁcation of chemoinvasion toward CXCL12 or FBS after treatment of BG-1 cells
with DIM and/or genistein. ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001; compared with control + chemoattractant.8 Journal of Oncology
extended period of time inhibit the growth of both ER+
and ER− breast cancer cells, low doses of genistein (<1μM)
appear to stimulate the growth of ER+ breast cancer cells
[21, 22]. Interestingly, CXCL12 has been shown to mediate
the proliferative eﬀects of estradiol in breast cancer cells
[23]. We noted a signiﬁcant increase in CXCL12 mRNA after
treatment with low doses (1–10μM) of genistein in MCF-
7 cells, although this eﬀect was not seen in MDA-MB-231
or BG-1 cells. An upregulation of CXCL12 by low doses
of genistein remains to be conﬁrmed in tissues that serve
as common sites of metastasis such as the lung and bone.
However, in light of what is known about the toxic and
potentially carcinogenic eﬀects of genistein, this observation
underscores the importance of thorough safety analyses
prior to condoning the use of phytochemicals as dietary
supplements. In particular, it highlights the importance of
dose, especially at the tissue level, when assessing the impact
of genistein on the development and progression of breast
and other cancers.
The doses of genistein and DIM described here are likely
achievable in humans upon supplementation, especially at
the tissue level. Total genistein plasma concentrations of up
to 20μM were obtained after feeding human volunteers a
genistein supplement [24–26]. Furthermore, genistein was
found to accumulate in certain organs to considerablyhigher
concentrations [27], and this is likely to be the case for
fatty tissues, such as the breast, in particular. When mice
were administered a single oral dose of DIM, a serum
concentration of approximately 5μM was achieved. Much
higher concentrations accumulated in certain organs [28].
Thus, the concentrations of genistein and DIM that we have
used in our studies are likely to reﬂect attainable doses in the
human.
Since CXCR4 and CXCL12 are implicated in the pro-
gression of many diﬀerent cancers, it is of interest to
determine whether DIM and/or genistein downregulate
these proteins in cancer cell lines of other origins. It
will also be important to investigate whether CXCL12 is
downregulated by phytochemicals in tissues that serve as
preferredsitesofmetastasisforthesecancers,suchasthelung
and bone. Furthermore, since many other phytochemicals
have been implicated in cancer protection, it will be prudent
to determine whether phytochemicals other than DIM and
genistein exert similar eﬀects on CXCR4 and CXCL12 levels.
Finally, phytochemicals in combination should be tested
in vivo to determine whether a potentiated eﬀect can be
achieved.
5. Conclusion
DIM has been suggested as a potential chemotherapeutic
for ER+ breast cancers. Surprisingly however, we have
found that DIM and genistein downregulate CXCR4 and
CXCL12 in both ER+ and ER− cell lines, indicating that
these phytochemicals may be eﬀective in the treatment of
both early- and late-stage breast cancers. Eﬀective therapies
for advanced disease are lacking, and the potential use of
compoundsasinnocuousasphytochemicalsfortreatmentof
either early- or late-stage cancers is an attractive alternative.
Furthermore, the increased response of CXCR4 and CXCL12
downregulation by DIM and genistein in combination may
prove useful in eliciting a potentiated eﬀect in vivo and
perhaps allow for optimization of the associated biological
responses.
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